您的位置：首页 > 产品中心 > 220991-20-8， Lumiracoxib
Lumiracoxib
产品价格查看更多规格...
| 产品编号 | 包装单位 | 单价(元) | 国内现货 | 国外库存 | 询价单 |
| 4119960 | 10 MG | 494 | 2-5天 | 4-6周 | |
| 4119960 | 50 MG | 1840 | 2-5天 | 4-6周 |
产品别名
220991-20-8
Lumiracoxib
COX-189
COX189
5-Methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid
LMX
CGS-35189
CGS 35189
CGS35189
2-[(2-Chloro-6-fluorophenyl)amino]-5-methyl-benzeneacetic acid
COX 189
Non-steroidal anti-inflammatory drug
结构式
基本信息
| Empirical Formula【经验(实验)分子式】 | C15H13ClFNO2 |
| Molecular weight | 293.72 |
| MDL number | MFCD07186254 |
| Biochem/physiol Actions【生化/生理作用】 | Lumiracoxib (COX189) is an orally active, potent and selective cyclooxygenase-2 inhibitor (Ki = 60 nM/COX-2 vs. 3.2 μM/COX-1) that inhibits COX-2-mediated PGE2 production in human whole blood (IC50 = 130 nM; stimulation = 50 μM A23187), but not COX-1-dependent TxB2 production (IC50 = 67 μM; stimulation = 10 μg/mL LPS). Lumiracoxib shows in vivo anti-inflammatory efficacy against carrageenan-induced paw oedema (ED30 = 0.35 mg/kg p.o.), CFA-induced hyperalgesia (ED30 = 5.1 mg/kg p.o.), as well as adjuvant-induced arthritis (ED50 = 3 mg/kg/day p.o.) in rats in vivo. |
产品性质
| Quality Level【质量水平】 | 100 |
| Assay【测定】 | ≥98% (HPLC) |
| form【形式】 | powder |
| color【颜色】 | white to beige |
| solubility【溶解性】 | DMSO: 2 mg/mL, clear |
| storage temp.【储存温度】 | 2-8℃ |
| SMILES string | ClC1=CC=CC(F)=C1NC2=CC=C(C)C=C2CC(O)=O |
安全信息
| Pictograms【象形图】 | GHS07 |
| Signal word【警示用语：】 | Warning |
| Hazard Statements | H302 |
| Precautionary Statements | P264 - P270 - P301 + P312 - P501 |
| Hazard Classifications【危险分类】 | Acute Tox. 4 Oral |
| Storage Class Code【储存分类代码】 | 11 - Combustible Solids |
| WGK | WGK 3 |
